Amgen settles with J&J on alleged Aranesp sales tactics – update
This article was originally published in Scrip
Executive Summary
Amgenhas agreed to resolve US litigation alleging that the firm used an illegal "tying arrangement" and pricing scheme to force cancer clinics to buy its Aranesp (darbepoetin alfa) rather than Ortho Biotech’s (Johnson & Johnson) Procrit (epoetin alfa). It will pay J&J $200 million to settle the antitrust lawsuit.